A multi-pronged scoping review approach to understanding the evolving implementation of the Smallpox and Polio eradication programs: what can other Global Health initiatives learn?


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
18 Dec 2020
Historique:
received: 16 08 2020
accepted: 24 08 2020
entrez: 19 12 2020
pubmed: 20 12 2020
medline: 17 3 2021
Statut: epublish

Résumé

Previous initiatives have aimed to document the history and legacy of the Smallpox Eradication Program (SEP) and the Global Polio Eradication Initiative (GPEI). In this multi-pronged scoping review, we explored the evolution and learning from SEP and GPEI implementation over time at global and country levels to inform other global health programs. Three related reviews of literature were conducted; we searched for documents on 1) the SEP and 2) GPEI via online database searches and also conducted global and national-level grey literature searches for documents related to the GPEI in seven purposively selected countries under the Synthesis and Translation of Research and Innovations from Polio Eradication (STRIPE) project. We included documents relevant to GPEI implementation. We conducted full text data analysis and captured data on Expert Recommendations for Implementing Change (ERIC) implementation strategies and principles, tools, outcomes, target audiences, and relevance to global health knowledge areas. 200 articles were included in the SEP scoping review, 1885 articles in the GPEI scoping review, and 963 documents in the grey literature review. M&E and engagement strategies were consistently translated from the SEP to GPEI; these evolved into newer approaches under the GPEI. Management strategies including setting up robust record systems also carried forward from SEP to GPEI; however, lessons around the need for operational flexibility in applying these strategies at national and sub-national levels did not. Similarly, strategies and lessons around conducting health systems readiness assessments prior to implementation were not carried forward from SEP to GPEI. Differences in the planning and communication strategies between the two programs included fidelity to implementation blueprints appeared to be higher under SEP, and independent monitoring boards and communication and media strategies were more prominent under GPEI. Linear learning did not always occur between SEP and GPEI; several lessons were lost and had to be re-learned. Implementation and adaptation of strategies in global health programs should be well codified, including information on the contextual, time and stakeholders' issues that elicit adaptations. Such description can improve the systematic translation of knowledge, and gains in efficiency and effectiveness of future global health programs.

Sections du résumé

BACKGROUND BACKGROUND
Previous initiatives have aimed to document the history and legacy of the Smallpox Eradication Program (SEP) and the Global Polio Eradication Initiative (GPEI). In this multi-pronged scoping review, we explored the evolution and learning from SEP and GPEI implementation over time at global and country levels to inform other global health programs.
METHODS METHODS
Three related reviews of literature were conducted; we searched for documents on 1) the SEP and 2) GPEI via online database searches and also conducted global and national-level grey literature searches for documents related to the GPEI in seven purposively selected countries under the Synthesis and Translation of Research and Innovations from Polio Eradication (STRIPE) project. We included documents relevant to GPEI implementation. We conducted full text data analysis and captured data on Expert Recommendations for Implementing Change (ERIC) implementation strategies and principles, tools, outcomes, target audiences, and relevance to global health knowledge areas.
RESULTS RESULTS
200 articles were included in the SEP scoping review, 1885 articles in the GPEI scoping review, and 963 documents in the grey literature review. M&E and engagement strategies were consistently translated from the SEP to GPEI; these evolved into newer approaches under the GPEI. Management strategies including setting up robust record systems also carried forward from SEP to GPEI; however, lessons around the need for operational flexibility in applying these strategies at national and sub-national levels did not. Similarly, strategies and lessons around conducting health systems readiness assessments prior to implementation were not carried forward from SEP to GPEI. Differences in the planning and communication strategies between the two programs included fidelity to implementation blueprints appeared to be higher under SEP, and independent monitoring boards and communication and media strategies were more prominent under GPEI.
CONCLUSIONS CONCLUSIONS
Linear learning did not always occur between SEP and GPEI; several lessons were lost and had to be re-learned. Implementation and adaptation of strategies in global health programs should be well codified, including information on the contextual, time and stakeholders' issues that elicit adaptations. Such description can improve the systematic translation of knowledge, and gains in efficiency and effectiveness of future global health programs.

Identifiants

pubmed: 33339517
doi: 10.1186/s12889-020-09439-1
pii: 10.1186/s12889-020-09439-1
pmc: PMC7747000
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1698

Subventions

Organisme : Bill and Melinda Gates Foundation
ID : N/A

Références

Vaccine. 2011 Dec 30;29 Suppl 4:D74-9
pubmed: 22486980
Vaccine. 2011 Dec 30;29 Suppl 4:D80-5
pubmed: 22486981
Public Health Rep. 1960 Jan;75:37-42
pubmed: 13840517
J Infect Dis. 2014 Nov 1;210 Suppl 1:S540-6
pubmed: 25316878
JAMA. 2008 Aug 20;300(7):839-41
pubmed: 18714066
J Infect Dis. 2014 Nov 1;210 Suppl 1:S91-7
pubmed: 25316881
BMJ Glob Health. 2019 Mar 7;4(2):e001257
pubmed: 30997169
JAMA. 1993 Oct 20;270(15):1859-60
pubmed: 8411530
Proc R Soc Lond B Biol Sci. 1977 Oct 19;199(1134):83-97
pubmed: 21417
Bull World Health Organ. 2014 May 1;92(5):314-5
pubmed: 24839319
Dev Biol (Basel). 2001;105:9-19
pubmed: 11763342
Cien Saude Colet. 2011 Feb;16(2):433-44
pubmed: 21340319
BMC Med Res Methodol. 2013 Apr 29;13:61
pubmed: 23627889
J Infect Dis. 2017 Jul 1;216(suppl_1):S15-S23
pubmed: 28838203
Vaccine. 2016 Apr 19;34(18):2074-81
pubmed: 26993330
World J Virol. 2012 Aug 12;1(4):108-14
pubmed: 24175215
Virol J. 2007 Jul 10;4:70
pubmed: 17623069
BMC Infect Dis. 2013 Jan 17;13:17
pubmed: 23327427
MMWR Morb Mortal Wkly Rep. 2012 Nov 2;61(43):883-5
pubmed: 23114256
J Infect Dis. 2014 Nov 1;210 Suppl 1:S16-22
pubmed: 25316831
J Infect Dis. 2017 Jul 1;216(suppl_1):S24-S32
pubmed: 28838189
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20130113
pubmed: 23798700
Biologicals. 1993 Dec;21(4):335-43
pubmed: 8024748
J Infect Dis. 2016 May 1;213 Suppl 3:S91-5
pubmed: 26609003
J Infect Dis. 2017 Jul 1;216(suppl_1):S94-S100
pubmed: 28838177
BMJ. 2013 Nov 20;347:f6753
pubmed: 24259324
Front Public Health. 2017 Mar 20;5:46
pubmed: 28373970
BMC Infect Dis. 2011 May 10;11:117
pubmed: 21569256
Clin Infect Dis. 1992 Feb;14(2):568-79
pubmed: 1554844
J R Soc Med. 2015 Dec;108(12):473-7
pubmed: 26432815
Bull World Health Organ. 2014 Jul 1;92(7):466
pubmed: 25110367
Bull World Health Organ. 2007 Jan;85(1):7-8
pubmed: 17242751
Bull World Health Organ. 1980;58(1):141-57
pubmed: 6966544
Ann Trop Med Parasitol. 2006 Jul-Sep;100(5-6):401-13
pubmed: 16899145
J Infect Dis. 2017 Jul 1;216(suppl_1):S355-S361
pubmed: 28838160
Vaccine. 2011 Dec 30;29 Suppl 4:D19-21
pubmed: 22486977
Bull World Health Organ. 1987;65(4):535-46
pubmed: 3319270
Vaccine. 1999 Oct 29;17 Suppl 3:S53-5
pubmed: 10559535
J Infect Dis. 2014 Nov 1;210 Suppl 1:S40-9
pubmed: 25316862
J Dev Areas. 1988 Apr;22(3):321-32
pubmed: 12342353
PLoS One. 2012;7(9):e46274
pubmed: 23050003
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
J Infect Dis. 2017 Jul 1;216(suppl_1):S183-S192
pubmed: 28838179
Hist Philos Life Sci. 1995;17(1):91-112
pubmed: 8552753
J Infect Dis. 2016 May 1;213 Suppl 3:S131-5
pubmed: 26908747
J Infect Dis. 2014 Nov 1;210 Suppl 1:S333-40
pubmed: 25316852
Implement Sci. 2015 Feb 12;10:21
pubmed: 25889199
Bull World Health Organ. 1999;77(7):602-6
pubmed: 10444884
Health Aff (Millwood). 2016 Feb;35(2):277-83
pubmed: 26858381

Auteurs

Meike Schleiff (M)

International Health Department, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA. mschlei4@jhu.edu.

Adetoun Olateju (A)

International Health Department, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA.

Ellie Decker (E)

International Health Department, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA.

Abigail H Neel (AH)

International Health Department, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA.

Rasheedat Oke (R)

International Health Department, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA.

Michael A Peters (MA)

International Health Department, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA.

Aditi Rao (A)

International Health Department, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA.

Olakunle Alonge (O)

International Health Department, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH